{"id":"bg2109","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BG2109 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"BG2109 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:09.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05738382","phase":"PHASE2","title":"Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures","status":"UNKNOWN","sponsor":"Bio Genuine (Shanghai) Biotech Co., Ltd.","startDate":"2023-08","conditions":"Assisted Reproductive Technology, Controlled Ovarian Hyperstimulation","enrollment":240},{"nctId":"NCT05894135","phase":"PHASE3","title":"Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis","status":"UNKNOWN","sponsor":"Bio Genuine (Shanghai) Biotech Co., Ltd.","startDate":"2023-07-14","conditions":"Endometriosis, Moderate to Severe Endometriosis-associated Pain","enrollment":540},{"nctId":"NCT05620355","phase":"PHASE3","title":"Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.","status":"UNKNOWN","sponsor":"Bio Genuine (Shanghai) Biotech Co., Ltd.","startDate":"2022-12-16","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BG2109","genericName":"BG2109","companyName":"Bio Genuine (Shanghai) Biotech Co., Ltd.","companyId":"bio-genuine-shanghai-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BG2109 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}